BioCentury
ARTICLE | Clinical News

TPI 287: Phase I started

July 21, 2014 7:00 AM UTC

Cortice said investigators at the University of California, San Francisco, began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate 2, 6.3 and 20 mg/m 2 IV TPI 287 once every 3 weeks for 9 weeks in about 66 patients with PSP or CBD. The trial includes an open-label extension phase in which patients will receive TPI 287 for an additional 6 weeks. The non-profit CBD Solutions is partially funding the trial. ...